Taiwan’s Biotech Industry, Lackluster or Late Bloomer? A Breakdown of Policies, Hotspots, and Market Movements
In this special series, we review the evolution of Taiwan’s biotech industry, focusing on key policies, bioclusters as well as the major deals surrounding licensing, mergers, and acquisitions. In the forthcoming articles, we will also present industry overviews, company analyses, and biotech investor interviews to depict the current landscape and predict future directions.
In the past, Taiwan built its ICT industry as a service provider which international brands could outsource. It can take a similar approach with its burgeoning CDMO industry to accumulate experience and technical knowledge. When considering manufacturing powerhouses such as South Korea and India, which have already established their CDMO markets, Taiwan’s industrial-scale...
In the past, Taiwan built its ICT industry as a service provider which international brands could outsource. It can take a similar approach with its burgeoning CDMO industry to accumulate experience and technical knowledge. When considering manufacturing powerhouses such as South Korea and India, which have already established their CDMO markets, Taiwan’s industrial-scale...
GO Prime with only $1.49 now
LATEST
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
2023-06-07
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023-06-05
EVENT
2023-06-05
Redefining Early Stage Investments (RESI) 2023 conference series – RESI Boston
Boston, USA